测试抗癌药物 Rogaratinib (BAY 1163877),用于治疗成纤维细胞生长因子受体 (FGFR 1-4) 发生改变的晚期肉瘤,以及 SDH 缺陷型胃肠道间质瘤 (GIST) 患者
Rogaratinib (BAY 1163877) 治疗成纤维细胞生长因子受体 (FGFR) 1-4 和 SDH 缺陷型胃肠道间质瘤 (GIST) 改变的肉瘤患者的 2 期研究
This phase II trial studies the effect of rogaratinib in treating patients with sarcoma with a change in a group of proteins called fibroblast growth factor receptors (FGFRs) or SDH-deficient gastrointestinal stromal tumor (GIST). Rogaratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
研究概览
地位
条件
详细说明
PRIMARY OBJECTIVE:
I. To estimate the objective radiographic response rate to single agent rogaratinib (BAY 1163877) in two cohorts of patients with sarcoma: Cohort A defined as patients with a sarcoma which harbors an alteration in fibroblast growth factor receptor (FGFR) 1, 2, 3 or 4 identified by next-generation sequencing profiling, and Cohort B defined as patients with advanced succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST).
SECONDARY OBJECTIVES:
I. To estimate progression-free survival (PFS) in patients in Cohort A and Cohort B treated with rogaratinib (BAY 1163877).
II. Further assessment for safety and tolerability.
EXPLORATORY OBJECTIVES:
I. To evaluate serial measurements of FGFR and FGFR ligand in serial tumor biopsies as potential pharmacodynamic markers of FGFR pathway inhibition by ribonucleic acid sequencing (RNA-seq) (pre-treatment biopsy and post-progression biopsy [if available]).
II. Whole exome sequencing (WES) of the pre-treatment biopsy and post-progression biopsy (if available) to help identify mechanisms of resistance.
III. To bank tumor material, germline deoxyribonucleic acid (DNA), and peripheral blood for potential future research for participating subjects who provide additional consent.
IV. To explore rogaratinib exposure with pharmacodynamics effects (i.e., clinical response, toxicity, and markers of FGFR pathway inhibition).
OUTLINE:
Patients receive rogaratinib orally (PO) twice daily (BID) on days 1-28 of each cycle. Treatment repeats every 28 days for up to 24 cycles (or up to July 31, 2027) in the absence of disease progression or unacceptable toxicity. Patients undergo biopsy at baseline and progression and computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET)-CT throughout the study. Patients may also undergo blood sample collection on study.
After completion of study treatment, patients are followed up at 30 days. After July 31, 2027, patients still on study are placed in observation on a drug holiday and are followed up every 3-6 months per standard of care until progression.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
California
-
Duarte、California、美国、91010
- City of Hope Comprehensive Cancer Center
-
Irvine、California、美国、92618
- City of Hope at Irvine Lennar
-
-
Colorado
-
Aurora、Colorado、美国、80045
- UCHealth University of Colorado Hospital
-
-
Florida
-
Miami、Florida、美国、33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Plantation、Florida、美国、33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Illinois
-
Chicago、Illinois、美国、60611
- Northwestern University
-
-
Maryland
-
Bethesda、Maryland、美国、20892
- National Institutes of Health Clinical Center
-
Bethesda、Maryland、美国、20892
- National Cancer Institute Developmental Therapeutics Clinic
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- University of Michigan Rogel Cancer Center
-
-
Missouri
-
Creve Coeur、Missouri、美国、63141
- Siteman Cancer Center at West County Hospital
-
St Louis、Missouri、美国、63110
- Washington University School of Medicine
-
St Louis、Missouri、美国、63129
- Siteman Cancer Center-South County
-
-
New York
-
New York、New York、美国、10065
- Memorial Sloan Kettering Cancer Center
-
-
Ohio
-
Columbus、Ohio、美国、43210
- Ohio State University Comprehensive Cancer Center
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15232
- UPMC Hillman Cancer Center
-
-
Tennessee
-
Nashville、Tennessee、美国、37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Houston、Texas、美国、77030
- UT MD Anderson Cancer Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Participant must have histologically confirmed sarcoma with FGFR alteration identified by next-generation sequencing profiling with the exception of SDH-deficient GIST who can be enrolled regardless of FGFR status. Initial testing can be performed on archival tissue, if available. Patients must have locally advanced or metastatic disease that is not amenable to surgery
-
Presence of measurable disease: Patient must have measurable disease
-
Patients must have progressed following at least one standard prior chemotherapy regimen with the exception of SDH-deficient GIST for which there is no standard of care
-
Participant must be willing to undergo pre-treatment biopsy if disease site is amenable to biopsy and low risk for the biopsy procedure. If biopsy is not possible, eligibility may be approved after discussion with the Study Chair. Of note, a minimum of 15 participants in each arm open to stage 2 should have disease amenable to biopsy. For those arms open in stage 1, all patients should have biopsiable disease.
-
Age >= 18 years
- Because no dosing or adverse event data are currently available on the use of rogaratinib (BAY 1163877) in patients <18 years of age, children are excluded from this study
-
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
-
Hemoglobin >= 8.0 g/dL
-
Absolute neutrophil count >= 1,000/mcL
-
Platelets >= 100,000/mcL
-
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
-
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3.0 x institutional ULN (unless liver metastases are present in which case it must be =< 5 x ULN)
-
Glomerular filtration rate (GFR) >= 60 mL/min/1.73 m^2 (using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula)
-
Human immunodeficiency virus (HIV)-infected patients on effective non-CYP3A4 interacting anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
-
Patients must be disease-free of prior invasive malignancies for > 5 years with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
- NOTE: If there is a history of prior malignancy, patients must not be receiving other specific treatment for that cancer
-
Patients should have completed prior treatment for their cancer: chemotherapy or radiotherapy must have been completed for greater than 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
-
Patients should have recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia
-
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification. To be eligible for this trial, patients should be class 2B or better
-
Patients must have a QTc interval length of below 450 millisecond (msec)
-
Participant is willing to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
-
Participant must be able to swallow and maintain pills
-
Women of childbearing potential must have a negative urine or serum pregnancy test within 28 days of initial dose of rogaratinib (BAY 1163877), and again within 7 days prior to treatment on day 1. If screening occurs within 7 days of day 1, only one pregnancy test is required
-
The effects of rogaratinib (BAY 1163877) on the developing human fetus are unknown. For this reason and because kinase inhibitor agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and 4 months after completion of rogaratinib (BAY 1163877). Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of rogaratinib (BAY 1163877) administration
-
Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible
Exclusion Criteria:
- Patients who are receiving any other investigational agents
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to rogaratinib (BAY 1163877)
- Concomitant administration with sensitive substrates/narrow therapeutic index drugs of CYP3A4, P-gp BCRP, MATE1, and MATE2K, and strong inhibitors and inducers of CYP3A4 should be avoided. Use caution with strong inhibitors and inducers of P-glycoprotein (gp). Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
- Concomitant administration of medications that prolong QT/QTc interval is prohibited in accordance with the published FDA guidance "E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs".
- Patients with disturbed calcium and/or phosphate metabolism are excluded from this study
- Patients with uncontrolled intercurrent illness
- Patients with psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study because rogaratinib (BAY 1163877) is kinase inhibitor agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with rogaratinib (BAY 1163877), breastfeeding should be discontinued if the mother is treated with rogaratinib (BAY 1163877)
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Treatment (rogaratinib)
Patients receive rogaratinib PO BID on days 1-28 of each cycle. Treatment repeats every 28 days for up to 24 cycles (or up to July 31, 2027) in the absence of disease progression or unacceptable toxicity. Patients undergo biopsy at baseline and progression and CT, MRI, and PET-CT throughout the study. Patients may also undergo blood sample collection on study. |
Undergo blood sample collection
其他名称:
Undergo MRI
其他名称:
Undergo biopsy
其他名称:
Undergo PET/CT scan
其他名称:
Undergo CT scan and PET/CT scan
其他名称:
Given PO
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Objective radiographic response
大体时间:Up to 30 days after removal from study
|
The duration of overall response is measured from the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). |
Up to 30 days after removal from study
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression-free survival
大体时间:From start of treatment to time of progression or death, whichever occurs first, assessed up to 30 days after removal from study
|
Will be estimated using Kaplan-Meier method. |
From start of treatment to time of progression or death, whichever occurs first, assessed up to 30 days after removal from study
|
|
Incidence of adverse events
大体时间:Up to completion of the 30-day follow up
|
Adverse events will be measured by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. |
Up to completion of the 30-day follow up
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Serial measurements of FGFR and FGFR ligand
大体时间:Up to 30 days after removal from study
|
Will be evaluated in serial tumor biopsies as potential pharmacodynamic markers of FGFR pathway inhibition by ribonucleic acid sequencing. Estimation of continuous biomarker measures will be via mean or median as appropriate and standard deviation. |
Up to 30 days after removal from study
|
|
Mechanisms of resistance
大体时间:Up to 30 days after removal from study
|
Will identify mechanisms of resistance via whole exome sequencing of pre- and post-treatment biopsies and considered exploratory. |
Up to 30 days after removal from study
|
|
Banking of tumor material, germline deoxyribonucleic acid, and peripheral blood
大体时间:Up to 30 days after removal from study
|
Will be banked for potential research. |
Up to 30 days after removal from study
|
合作者和调查者
调查人员
- 首席研究员:Suzanne George、Dana-Farber - Harvard Cancer Center LAO
出版物和有用的链接
一般刊物
- Matin SF, Adibi M, Shah AY, Alhalabi O, Corn P, Guo C, Amirtharaj R, Xiao L, Lange S, Duose DY, Wang S, Pal S, Campbell MT. Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma. J Urol. 2024 Jun;211(6):784-793. doi: 10.1097/JU.0000000000003928. Epub 2024 Apr 4.
- Merriam P, Morrow JJ, Mazzola E, Solimini NL, Gokhale PC, Chi P, Chen AP, Agulnik M, Burgess M, Schuetze SM, Somaiah N, Van Tine BA, Pollack SM, Tinoco G, Trent J, Wilky BA, Bothwick N, Eschle BK, Nguyen V, Beumer JH, Rastkari N, Jiwani S, Wu PI, Pelosof L, Hemming ML, Shapiro GI, Demetri G, Bernstein B, George S. Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial. Nat Med. 2026 Jun;32(6):2191-2200. doi: 10.1038/s41591-026-04376-9. Epub 2026 May 26.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- NCI-2020-08011
- UM1CA186709 (美国 NIH 拨款/合同)
- NCI-2020-08011 (注册表标识符:CTRP (Clinical Trial Reporting Program))
- 21-070
- 10411 (其他标识符:CTEP)
- 10411 (其他标识符:Dana-Farber - Harvard Cancer Center LAO)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.